{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:51:55Z","timestamp":1793379115136,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T00:00:00Z","timestamp":1548028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T00:00:00Z","timestamp":1548028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Choroidal neovascularization (CNV) is a major cause of visual impairment in patients suffering from wet age-related macular degeneration (AMD), particularly when refractory to intraocular anti-VEGF injections. Here we report that treatment with the oral mineralocorticoid receptor (MR) antagonist spironolactone reduces signs of CNV in patients refractory to anti-VEGF treatment. In animal models of wet AMD, pharmacological inhibition of the MR pathway or endothelial-specific deletion of MR inhibits CNV through VEGF-independent mechanisms, in part through upregulation of the extracellular matrix protein decorin. Intravitreal injections of spironolactone-loaded microspheres and systemic delivery lead to similar reductions in CNV. Together, our work suggests MR inhibition as a novel therapeutic option for wet AMD patients unresponsive to anti-VEGF drugs.<\/jats:p>","DOI":"10.1038\/s41467-018-08125-6","type":"journal-article","created":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T11:02:40Z","timestamp":1548068560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration"],"prefix":"10.1038","volume":"10","author":[{"given":"Min","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8822-8194","authenticated-orcid":false,"given":"Irmela","family":"Mantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Gelize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Arboleda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Seminel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinath","family":"Levy-Boukris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn","family":"Dernigoghossian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Prunotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Andrieu-Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0733-9950","authenticated-orcid":false,"given":"Carlo","family":"Rivolta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Canonica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Naud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Lechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolette","family":"Farman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bravo-Osuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Herrero-Vanrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Jaisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Behar-Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,21]]},"reference":[{"key":"8125_CR1","doi-asserted-by":"crossref","unstructured":"Wong, W. L.et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob. Health 2, e106\u2013e116 (2014).","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"8125_CR2","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","volume":"392","author":"P Mitchell","year":"2018","unstructured":"Mitchell, P., Liew, G., Gopinath, B. & Wong, T. Y. Age-related macular degeneration. Lancet 392, 1147\u20131159 (2018).","journal-title":"Lancet"},{"key":"8125_CR3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nature09830","volume":"471","author":"H Kaneko","year":"2011","unstructured":"Kaneko, H. et al. DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature 471, 325\u2013330 (2011).","journal-title":"Nature"},{"key":"8125_CR4","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/jcm4010172","volume":"4","author":"L Celkova","year":"2015","unstructured":"Celkova, L. & Doyle, S. L. & Campbell, M. . NLRP3 inflammasome and pathobiology in AMD. J. Clin. Med. 4, 172\u2013192 (2015).","journal-title":"J. Clin. Med."},{"key":"8125_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2014.11.005","volume":"45","author":"SS Whitmore","year":"2015","unstructured":"Whitmore, S. S. et al. Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy. Prog. Retin. Eye Res. 45, 1\u201329 (2015).","journal-title":"Prog. Retin. Eye Res."},{"key":"8125_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1350-9462(02)00043-5","volume":"22","author":"AN Witmer","year":"2003","unstructured":"Witmer, A. N., Vrensen, G. F. J. M., Van Noorden, C. J. F. & Schlingemann, R. O. Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retin. Eye Res. 22, 1\u201329 (2003).","journal-title":"Prog. Retin. Eye Res."},{"key":"8125_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.mam.2012.04.005","volume":"33","author":"I Bhutto","year":"2012","unstructured":"Bhutto, I. & Lutty, G. Understanding age-related macular degeneration (AMD): relationships between the photoreceptor\/retinal pigment epithelium\/Bruch\u2019s membrane\/choriocapillaris complex. Mol. Asp. Med. 33, 295\u2013317 (2012).","journal-title":"Mol. Asp. Med."},{"key":"8125_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.preteyeres.2015.06.002","volume":"49","author":"PA Campochiaro","year":"2015","unstructured":"Campochiaro, P. A. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog. Retin. Eye Res. 49, 67\u201381 (2015).","journal-title":"Prog. Retin. Eye Res."},{"key":"8125_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2006.09.002","volume":"26","author":"SX Zhang","year":"2007","unstructured":"Zhang, S. X. & Ma, J. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog. Retin. Eye Res. 26, 1\u201337 (2007).","journal-title":"Prog. Retin. Eye Res."},{"key":"8125_CR10","first-page":"5397","volume":"9","author":"J Ba","year":"2015","unstructured":"Ba, J. et al. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. Drug Des. Devel. Ther. 9, 5397\u20135405 (2015).","journal-title":"Drug Des. Devel. Ther."},{"key":"8125_CR11","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1167\/iovs.16-19772","volume":"57","author":"S Rezar-Dreindl","year":"2016","unstructured":"Rezar-Dreindl, S. et al. The intraocular cytokine profile and therapeutic response in persistent neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 57, 4144\u20134150 (2016).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"8125_CR12","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","volume":"123","author":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group.","year":"2016","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The comparison of age-related macular degeneration treatments trials. Ophthalmology 123, 1751\u20131761 (2016).","journal-title":"Ophthalmology"},{"key":"8125_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ajo.2014.05.007","volume":"158","author":"RB Rush","year":"2014","unstructured":"Rush, R. B., Rush, S. W., Aragon, A. V. & Ysasaga, J. E. Evaluation of choroidal neovascularization with indocyanine green angiography in neovascular age-related macular degeneration subjects undergoing intravitreal bevacizumab therapy. Am. J. Ophthalmol. 158, 337\u2013344 (2014).","journal-title":"Am. J. Ophthalmol."},{"key":"8125_CR14","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1167\/iovs.09-4496","volume":"51","author":"C Framme","year":"2010","unstructured":"Framme, C., Panagakis, G. & Birngruber, R. Effects on choroidal neovascularization after anti-VEGF Upload using intravitreal ranibizumab, as determined by spectral domain-optical coherence tomography. Invest. Ophthalmol. Vis. Sci. 51, 1671\u20131676 (2010).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"8125_CR15","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2147\/DDDT.S115121","volume":"10","author":"S Yang","year":"2016","unstructured":"Yang, S., Zhao, J. & Sun, X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des. Devel. Ther. 10, 1857\u20131867 (2016).","journal-title":"Drug Des. Devel. Ther."},{"key":"8125_CR16","doi-asserted-by":"publisher","first-page":"6911","DOI":"10.1167\/iovs.16-21201","volume":"57","author":"JW Miller","year":"2016","unstructured":"Miller, J. W. Beyond VEGF-the weisenfeld lecture. Invest. Ophthalmol. Vis. Sci. 57, 6911\u20136918 (2016).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"8125_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-016-0207-3","volume":"16","author":"JJ Arnold","year":"2016","unstructured":"Arnold, J. J., Markey, C. M., Kurstjens, N. P. & Guymer, R. H. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration\u2013a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol. 16, 31 (2016).","journal-title":"BMC Ophthalmol."},{"key":"8125_CR18","doi-asserted-by":"crossref","unstructured":"CATT Research Group, .et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364, 1897\u20131908 (2011).","DOI":"10.1056\/NEJMoa1102673"},{"key":"8125_CR19","doi-asserted-by":"publisher","unstructured":"Gewaily, D., Muthuswamy, K. & Greenberg, P. B. Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst. Rev. CD007324 (2015). https:\/\/doi.org\/10.1002\/14651858.CD007324.pub3","DOI":"10.1002\/14651858.CD007324.pub3"},{"key":"8125_CR20","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.ophtha.2014.04.012","volume":"121","author":"JH Cao","year":"2014","unstructured":"Cao, J. H., Mulvahill, M., Zhang, L., Joondeph, B. C. & Dacey, M. S. Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation. Ophthalmology 121, 1871\u20131876 (2014).","journal-title":"Ophthalmology"},{"key":"8125_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1167\/iovs.17-22259","volume":"59","author":"SM Whitcup","year":"2018","unstructured":"Whitcup, S. M., Cidlowski, J. A., Csaky, K. G. & Ambati, J. Pharmacology of corticosteroids for diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 59, 1\u201312 (2018).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"8125_CR22","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1096\/fj.09-154344","volume":"24","author":"M Zhao","year":"2010","unstructured":"Zhao, M. et al. The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in M\u00fcller glial cells. Faseb J. 24, 3405\u20133415 (2010).","journal-title":"Faseb J."},{"key":"8125_CR23","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1172\/JCI61427","volume":"122","author":"M Zhao","year":"2012","unstructured":"Zhao, M. et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J. Clin. Invest. 122, 2672\u20132679 (2012).","journal-title":"J. Clin. Invest."},{"key":"8125_CR24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","volume":"48","author":"A Daruich","year":"2015","unstructured":"Daruich, A. et al. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog. Retin. Eye Res. 48, 82\u2013118 (2015).","journal-title":"Prog. Retin. Eye Res."},{"key":"8125_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/tvst.5.2.2","volume":"5","author":"A Daruich","year":"2016","unstructured":"Daruich, A. et al. Oral mineralocorticoid-receptor antagonists: Real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy. Transl. Vis. Sci. Technol. 5, 2 (2016).","journal-title":"Transl. Vis. Sci. Technol."},{"key":"8125_CR26","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1097\/IAE.0000000000000614","volume":"35","author":"E Bousquet","year":"2015","unstructured":"Bousquet, E. et al. Spironolactone for nonresolving central serous chorioretinopathy: A randomized controlled crossover study. Retina 35, 2505\u20132515 (2015).","journal-title":"Retina"},{"key":"8125_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1124\/pr.115.011106","volume":"68","author":"F Jaisser","year":"2016","unstructured":"Jaisser, F. & Farman, N. Emerging roles of the mineralocorticoid receptor in pathology: Toward new paradigms in clinical pharmacology. Pharmacol. Rev. 68, 49\u201375 (2016).","journal-title":"Pharmacol. Rev."},{"key":"8125_CR28","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1126\/science.2416056","volume":"230","author":"R Crum","year":"1985","unstructured":"Crum, R., Szabo, S. & Folkman, J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 230, 1375\u20131378 (1985).","journal-title":"Science"},{"key":"8125_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jsbmb.2011.12.014","volume":"129","author":"M Fujii","year":"2012","unstructured":"Fujii, M. et al. Aldosterone inhibits endothelial morphogenesis and angiogenesis through the downregulation of vascular endothelial growth factor receptor-2 expression subsequent to peroxisome proliferator-activated receptor gamma. J. Steroid Biochem. Mol. Biol. 129, 145\u2013152 (2012).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"8125_CR30","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1161\/01.CIR.0000127112.36796.9B","volume":"109","author":"F Michel","year":"2004","unstructured":"Michel, F. et al. Aldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathway. Circulation 109, 1933\u20131937 (2004).","journal-title":"Circulation"},{"key":"8125_CR31","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1097\/01.hjh.0000249698.26983.4e","volume":"24","author":"A Miternique-Grosse","year":"2006","unstructured":"Miternique-Grosse, A. et al. Antiangiogenic effects of spironolactone and other potassium-sparing diuretics in human umbilical vein endothelial cells and in fibrin gel chambers implanted in rats. J. Hypertens. 24, 2207\u20132213 (2006).","journal-title":"J. Hypertens."},{"key":"8125_CR32","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1161\/CIRCRESAHA.108.176008","volume":"104","author":"JL Wilkinson-Berka","year":"2009","unstructured":"Wilkinson-Berka, J. L., Tan, G., Jaworski, K. & Miller, A. G. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ. Res. 104, 124\u2013133 (2009).","journal-title":"Circ. Res."},{"key":"8125_CR33","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.preteyeres.2010.05.003","volume":"29","author":"HE Grossniklaus","year":"2010","unstructured":"Grossniklaus, H. E., Kang, S. J. & Berglin, L. Animal models of choroidal and retinal neovascularization. Prog. Retin. Eye Res. 29, 500\u2013519 (2010).","journal-title":"Prog. Retin. Eye Res."},{"key":"8125_CR34","doi-asserted-by":"publisher","first-page":"T125","DOI":"10.1530\/JOE-16-0600","volume":"234","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof, P. & B\u00e4rfacker, L. 30 Years of the mineralocorticoid receptor: Mineralocorticoid receptor antagonists: 60 years of research and development. J. Endocrinol. 234, T125\u2013T140 (2017).","journal-title":"J. Endocrinol."},{"key":"8125_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jconrel.2017.09.029","volume":"266","author":"M Zhao","year":"2017","unstructured":"Zhao, M. et al. Tolerance of high and low amounts of PLGA microspheres loaded with mineralocorticoid receptor antagonist in retinal target site. J. Control. Release 266, 187\u2013197 (2017).","journal-title":"J. Control. Release"},{"key":"8125_CR36","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1093\/eurheartj\/eht095","volume":"34","author":"N Sch\u00e4fer","year":"2013","unstructured":"Sch\u00e4fer, N. et al. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. Eur. Heart J. 34, 3515\u20133524 (2013).","journal-title":"Eur. Heart J."},{"key":"8125_CR37","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ophtha.2012.07.038","volume":"120","author":"JW Miller","year":"2013","unstructured":"Miller, J. W., Le Couter, J., Strauss, E. C. & Ferrara, N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology 120, 106\u2013114 (2013).","journal-title":"Ophthalmology"},{"key":"8125_CR38","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ophtha.2003.05.030","volume":"111","author":"TW Olsen","year":"2004","unstructured":"Olsen, T. W., Feng, X., Kasper, T. J., Rath, P. P. & Steuer, E. R. Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. Ophthalmology 111, 250\u2013255 (2004).","journal-title":"Ophthalmology"},{"key":"8125_CR39","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.ajo.2014.07.006","volume":"158","author":"JJ Jung","year":"2014","unstructured":"Jung, J. J. et al. The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration. Am. J. Ophthalmol. 158, 769\u2013779.e2 (2014).","journal-title":"Am. J. Ophthalmol."},{"key":"8125_CR40","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier, J. S. et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119, 2537\u20132548 (2012).","journal-title":"Ophthalmology"},{"key":"8125_CR41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/14728214.2017.1362390","volume":"22","author":"RM Hussain","year":"2017","unstructured":"Hussain, R. M. & Ciulla, T. A. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration. Exp. Opin. Emerg. Drugs 22, 235\u2013246 (2017).","journal-title":"Exp. Opin. Emerg. Drugs"},{"key":"8125_CR42","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40123-016-0075-1","volume":"6","author":"KG Kapoor","year":"2017","unstructured":"Kapoor, K. G., Todi, N. & Wagner, A. L. Mineralocorticoid antagonists as adjuncts in neovascular age-related macular degeneration. Ophthalmol. Ther. 6, 141\u2013146 (2017).","journal-title":"Ophthalmol. Ther."},{"key":"8125_CR43","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/978-1-4614-3209-8_26","volume":"801","author":"M Grunin","year":"2014","unstructured":"Grunin, M., Hagbi-Levi, S. & Chowers, I. The role of monocytes and macrophages in age-related macular degeneration. Adv. Exp. Med. Biol. 801, 199\u2013205 (2014).","journal-title":"Adv. Exp. Med. Biol."},{"key":"8125_CR44","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1172\/JCI31692","volume":"117","author":"C Combadi\u00e8re","year":"2007","unstructured":"Combadi\u00e8re, C. et al. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J. Clin. Invest. 117, 2920\u20132928 (2007).","journal-title":"J. Clin. Invest."},{"key":"8125_CR45","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1172\/JCI41080","volume":"120","author":"MG Usher","year":"2010","unstructured":"Usher, M. G. et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J. Clin. Invest. 120, 3350\u20133364 (2010).","journal-title":"J. Clin. Invest."},{"key":"8125_CR46","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","volume":"93","author":"J Barrera-Chimal","year":"2018","unstructured":"Barrera-Chimal, J. et al. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney Int. 93, 1344\u20131355 (2018).","journal-title":"Kidney Int."},{"key":"8125_CR47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.matbio.2015.01.023","volume":"43","author":"H J\u00e4rvel\u00e4inen","year":"2015","unstructured":"J\u00e4rvel\u00e4inen, H., Sainio, A. & Wight, T. N. Pivotal role for decorin in angiogenesis. Matrix Biol. 43, 15\u201326 (2015).","journal-title":"Matrix Biol."},{"key":"8125_CR48","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.exer.2016.08.015","volume":"151","author":"J Frikeche","year":"2016","unstructured":"Frikeche, J., Maiti, G. & Chakravarti, S. Small leucine-rich repeat proteoglycans in corneal inflammation and wound healing. Exp. Eye Res. 151, 142\u2013149 (2016).","journal-title":"Exp. Eye Res."},{"key":"8125_CR49","doi-asserted-by":"publisher","first-page":"7528","DOI":"10.1167\/iovs.12-10797","volume":"53","author":"TDL Keenan","year":"2012","unstructured":"Keenan, T. D. L. et al. Mapping the differential distribution of proteoglycan core proteins in the adult human retina, choroid, and sclera. Invest. Ophthalmol. Vis. Sci. 53, 7528\u20137538 (2012).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"8125_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.matbio.2016.09.009","volume":"55","author":"MA Gubbiotti","year":"2016","unstructured":"Gubbiotti, M. A., Vallet, S. D., Ricard-Blum, S. & Iozzo, R. V. Decorin interacting network: A comprehensive analysis of decorin-binding partners and their versatile functions. Matrix Biol. 55, 7\u201321 (2016).","journal-title":"Matrix Biol."},{"key":"8125_CR51","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0002-9440(10)63975-2","volume":"158","author":"L Nelimarkka","year":"2001","unstructured":"Nelimarkka, L. et al. Decorin is produced by capillary endothelial cells in inflammation-associated angiogenesis. Am. J. Pathol. 158, 345\u2013353 (2001).","journal-title":"Am. J. Pathol."},{"key":"8125_CR52","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1159\/000081806","volume":"41","author":"E Sch\u00f6nherr","year":"2004","unstructured":"Sch\u00f6nherr, E. et al. Decorin deficiency leads to impaired angiogenesis in injured mouse cornea. J. Vasc. Res. 41, 499\u2013508 (2004).","journal-title":"J. Vasc. Res."},{"key":"8125_CR53","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.addr.2015.10.016","volume":"97","author":"T Neill","year":"2016","unstructured":"Neill, T., Schaefer, L. & Iozzo, R. V. Decorin as a multivalent therapeutic agent against cancer. Adv. Drug Deliv. Rev. 97, 174\u2013185 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"8125_CR54","doi-asserted-by":"publisher","first-page":"5492","DOI":"10.1074\/jbc.M111.283499","volume":"287","author":"T Neill","year":"2012","unstructured":"Neill, T. et al. Decorin antagonizes the angiogenic network: concurrent inhibition of Met, hypoxia inducible factor 1\u03b1, vascular endothelial growth factor A, and induction of thrombospondin-1 and TIMP3. J. Biol. Chem. 287, 5492\u20135506 (2012).","journal-title":"J. Biol. Chem."},{"key":"8125_CR55","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.exer.2013.08.019","volume":"116","author":"S Du","year":"2013","unstructured":"Du, S., Wang, S., Wu, Q., Hu, J. & Li, T. Decorin inhibits angiogenic potential of choroid-retinal endothelial cells by downregulating hypoxia-induced Met, Rac1, HIF-1\u03b1 and VEGF expression in cocultured retinal pigment epithelial cells. Exp. Eye Res. 116, 151\u2013160 (2013).","journal-title":"Exp. Eye Res."},{"key":"8125_CR56","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1182\/blood.V98.7.2124","volume":"98","author":"J Xaus","year":"2001","unstructured":"Xaus, J., Comalada, M., Card\u00f3, M., Valledor, A. F. & Celada, A. Decorin inhibits macrophage colony-stimulating factor proliferation of macrophages and enhances cell survival through induction of p27(Kip1) and p21(Waf1). Blood 98, 2124\u20132133 (2001).","journal-title":"Blood"},{"key":"8125_CR57","doi-asserted-by":"publisher","first-page":"e26432","DOI":"10.1371\/journal.pone.0026432","volume":"6","author":"RR Mohan","year":"2011","unstructured":"Mohan, R. R. et al. Targeted decorin gene therapy delivered with adeno-associated virus effectively retards corneal neovascularization in vivo. PLoS ONE 6, e26432 (2011).","journal-title":"PLoS ONE"},{"key":"8125_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10124-4","volume":"7","author":"X Wang","year":"2017","unstructured":"Wang, X. et al. TGF-\u03b2 participates choroid neovascularization through Smad2\/3-VEGF\/TNF-\u03b1 signaling in mice with Laser-induced wet age-related macular degeneration. Sci. Rep. 7, 9672 (2017).","journal-title":"Sci. Rep."},{"key":"8125_CR59","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1074\/mcp.M900523-MCP200","volume":"9","author":"X Yuan","year":"2010","unstructured":"Yuan, X. et al. Quantitative proteomics: comparison of the macular Bruch membrane\/choroid complex from age-related macular degeneration and normal eyes. Mol. Cell. Proteom. 9, 1031\u20131046 (2010).","journal-title":"Mol. Cell. Proteom."},{"key":"8125_CR60","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1097\/IAE.0000000000001303","volume":"37","author":"R Gergely","year":"2017","unstructured":"Gergely, R. et al. Mineralocorticoid receptor antagonist treatment in bilateral chronic central serous chorioretinopathy: A comparative study of exudative and nonexudative fellow eyes. Retina 37, 1084\u20131091 (2017).","journal-title":"Retina"},{"key":"8125_CR61","doi-asserted-by":"publisher","first-page":"T17","DOI":"10.1530\/JOE-17-0119","volume":"234","author":"J Funder","year":"2017","unstructured":"Funder, J. 30 years of the mineralocorticoid receptor: Mineralocorticoid receptor activation and specificity-conferring mechanisms: a brief history. J. Endocrinol. 234, T17\u2013T21 (2017).","journal-title":"J. Endocrinol."},{"key":"8125_CR62","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1681\/ASN.2016040477","volume":"28","author":"J Barrera-Chimal","year":"2017","unstructured":"Barrera-Chimal, J. et al. Benefit of mineralocorticoid receptor antagonism in AKI: Role of vascular smooth muscle Rac1. J. Am. Soc. Nephrol. 28, 1216\u20131226 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"8125_CR63","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1023\/A:1008942828960","volume":"8","author":"BE Clausen","year":"1999","unstructured":"Clausen, B. E., Burkhardt, C., Reith, W., Renkawitz, R. & F\u00f6rster, I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic. Res. 8, 265\u2013277 (1999).","journal-title":"Transgenic. Res."},{"key":"8125_CR64","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1161\/HYPERTENSIONAHA.115.06172","volume":"66","author":"KB Mueller","year":"2015","unstructured":"Mueller, K. B. et al. Endothelial mineralocorticoid receptors differentially contribute to coronary and mesenteric vascular function without modulating blood pressure. Hypertension 66, 988\u2013997 (2015).","journal-title":"Hypertension"},{"key":"8125_CR65","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","volume":"123","author":"D Fraccarollo","year":"2011","unstructured":"Fraccarollo, D. et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 123, 400\u2013408 (2011).","journal-title":"Circulation"},{"key":"8125_CR66","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nature09002","volume":"465","author":"Y Wang","year":"2010","unstructured":"Wang, Y. et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 465, 483\u2013486 (2010).","journal-title":"Nature"},{"key":"8125_CR67","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/dvg.20448","volume":"47","author":"O Wendling","year":"2009","unstructured":"Wendling, O., Bornert, J. -M., Chambon, P. & Metzger, D. Efficient temporally-controlled targeted mutagenesis in smooth muscle cells of the adult mouse. Genesis 47, 14\u201318 (2009).","journal-title":"Genesis"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-08125-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-08125-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-08125-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T19:30:06Z","timestamp":1671219006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-08125-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,21]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["8125"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-08125-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,21]]},"assertion":[{"value":"30 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.Z. and F.B.-C. are listed as inventors in a patent application related to the \u201cMethods and pharmaceutical compositions for the treatment of choroidal neovascularization\u201d (WO2017064121A1, ). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"369"}}